Abstract

Association between statin use and inflammatory bowel diseases: Results from a Swedish, nationwide, population-based case-control study

J Crohns Colitis. 2020 Nov 20;jjaa235. doi: 10.1093/ecco-jcc/jjaa235. Online ahead of print.

Paul Lochhead 1 2, Hamed Khalili 1 2, Michael C Sachs 3, Andrew T Chan 1 2, Ola Olén 3 4 5, Jonas F Ludvigsson 6 7

 
     

Author information

  • 1Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • 2Division of Gastroenterology, Massachusetts General Hospital, Boston, MA.
  • 3Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • 4Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • 5Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden.
  • 6Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • 7Department of Pediatrics, Örebro University Hospital, Orebro, Sweden.

Abstract

Background: In addition to their potent lipid-lowering action, statins may modulate inflammation. However, data on statin use and the risk of inflammatory bowel diseases (IBD) have been inconsistent.

Methods: We searched the Nationwide Swedish Patient Register (inpatient and non-primary outpatient care) to identify adults diagnosed with Crohn's disease (CD, n=7,637) or ulcerative colitis (UC, n=15,652) from 2006-2014. Each case was matched to 10 general population controls (n=232,890). Data on dispensed statin prescriptions were extracted from the Prescribed Drug Register. Conditional logistic regression models estimated odds ratios (ORs) for risk of IBD according to statin exposure while controlling for potential confounders, including indications for statin therapy.

Results: In multivariable adjusted models, compared to no statin use, any statin use was associated with a lower risk of CD (OR=0.71; 95% CI, 0.63-0.79), but not UC (OR=1.03; 95% CI, 0.96-1.11). The lowest OR for CD was seen for current statin use (OR=0.67; 95% CI, 0.60-0.75). For CD, the lowest category of cumulative statin dose (31-325 defined daily dose, DDD) was associated with an OR of 0.73 (95% CI, 0.61-0.88) and the highest category (>1500 DDD) with an OR of 0.66 (95% CI, 0.55-0.80), Ptrend=0.10. For UC, the lowest and highest dose categories yielded ORs of 1.12 (95% CI, 1.00-1.25) and 0.99 (95% CI, 0.88-1.13), respectively, Ptrend=0.13.

Conclusions: Statin use was associated with a lower risk of CD, but not UC. The association with CD risk appeared strongest for current statin use. Our findings suggest that statin use may influence the development of CD.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.